Kidney cancer has historically been one of the most difficult cancers to treat. Research developments in immunotherapy and targeted treatments have resulted in advances that have helped patients live longer, higher-quality lives, including the development of several new drugs that target vulnerable pathways in cancer cells.

Survival rates for kidney cancer have improved steadily since the early 1980s. While they remain lower than other cancers, a wide range of research is underway to expand treatment options and improve the lives of patients with the disease.